Spots Global Cancer Trial Database for recurrent epithelial ovarian cancer
Every month we try and update this database with for recurrent epithelial ovarian cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer | NCT05444270 | Recurrent Epith... | Standard salvag... Standard salvag... | 19 Years - | Yonsei University | |
| Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | NCT05700669 | Metastatic Cast... Recurrent Epith... Breast Cancer | AsiDNA Olaparib | 18 Years - | Valerio Therapeutics | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | NCT01334047 | Recurrent Epith... | DC-006 vaccine | 18 Years - 75 Years | Oslo University Hospital | |
| Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | NCT01815528 | Recurrent Epith... | Catumaxomab | 18 Years - | Charite University, Berlin, Germany | |
| Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | NCT01815528 | Recurrent Epith... | Catumaxomab | 18 Years - | Charite University, Berlin, Germany | |
| Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | NCT01334047 | Recurrent Epith... | DC-006 vaccine | 18 Years - 75 Years | Oslo University Hospital | |
| Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | NCT00968799 | Epithelial Ovar... Fallopian Tube ... | Hyperthermic in... Cytoreduction Cisplatin | 18 Years - 70 Years | Cantonal Hospital of St. Gallen | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | NCT05700669 | Metastatic Cast... Recurrent Epith... Breast Cancer | AsiDNA Olaparib | 18 Years - | Valerio Therapeutics | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene | |
| Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer | NCT05444270 | Recurrent Epith... | Standard salvag... Standard salvag... | 19 Years - | Yonsei University | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
